Additionally, clinical trials with CRISPR-Cas9-mediated PD-1-knock-out autologous T cells are also underway for prostate cancer (NCT02867345), bladder cancer (NCT02863913), and renal cell carcinoma (NCT02867332) [403]. Here, PDCD1 is linked to renal cell carcinoma.